BEIJING -- The domestically-developed jumbo jet C919, aircraft engines and other high-end aviation products will be highlighted at Aviation Expo China 2017 in Beijing from Sept 19 to 22, the event organizer said Wednesday. The expo will be held at China National Convention Center and is being jointly organized by Commercial Aircraft Corp of China (COMAC), Aero Engine Corporation of China (AECC) and China Promotion Ltd. COMAC will display the Chinese-developed large passenger jet C919, new regional jet ARJ21, and a wide-body passenger jet, which will be jointly built by China and Russia. The C919 achieved a successful maiden flight on May 5 this year, and has moved to the next phase of further testing and test flight missions, according to COMAC. The wide-body passenger jet program is currently in the preparation phase of the proposal, after the joint venture China-Russia Commercial Aircraft International Co, Ltd (CRAIC) was set up on May 22 this year. The newly-established AECC will display its achievements in aircraft engines, gas turbines, and graphene material and high precision aluminum alloy technologies, it said. The AECC was set up in Beijing on Aug 28, 2016 to accelerate independent research, development and manufacturing of aircraft engines and gas turbines. Founded in 1984, China Aviation Expo was China's first professional aviation expo. This year it has attracted more than 300 exhibitors from 14 countries and regions, with eight national pavilions, including Russia, Ukraine, Italy and Australia. personalised silicone wristbandswristbands with a messageblack rubber braceletsentrance wristbands24 wristbandscustom wrist sweatbandsrubber bracelet makerwristband keychaindebossed wristbandwristbands online
BEIJING -- China is working to reduce the prices of cancer drugs and the financial burden on patients, according to health officials Saturday. Prices of cancer drugs will be reduced through centralized negotiations and procurement, Zeng Yixin, vice director of the National Health Commission, said at a press conference. According to Chen Jinfu, head of the medical insurance department of the Ministry of Human Resources and Social Security, last year the government reached agreements with pharmaceutical enterprises on the prices of 36 cancer medicines on the medical insurance list. Prices of these drugs have been marked down by 44 percent on average, Chen said. Stressing a patient-centered approach in negotiations, the official also noted that market competition is also needed. The government will work to include more antineoplastic drugs into the country's catalogue of medical insurance reimbursement, which already incorporates most of the relevant drugs. Moreover, efforts have been made in accelerating the review and approval procedures for new medicines, reducing circulation costs and improving diagnosis to reduce the burden on patients and their families, Zeng said. The average approval time for imported drugs has been significantly shortened, and the customs clearance procedures streamlined, said Li Jinju, an official with China Food and Drug Administration. The Ministry of Finance announced Monday that China will exempt 28 drugs from import tariffs, including all cancer drugs from May 1, as part of wider opening of the market. Admitting that the tariff cut may challenge China's domestic pharmaceutical industry, Liu Dengfeng of the health commission expressed confidence in tackling it. China's medical research and development has progressed in recent years with the talent pool getting stronger and innovation booming, he said.
